Summary of Presentations from the Takeda Pharmaceuticals International-Sponsored Symposium, held at the 50th Annual Meeting of the EASD, Vienna, Austria, on 15th September 2014
Chairperson: Heinz Drexel1
Speakers: Jørgen Rungby,2 Jochen Seufert,3 Kausik Ray4
1. Department of Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Private University in the Principality of Liechtenstein, Triesen, Liechtenstein
2. Aarhus University, Aarhus, Denmark
3. University of Freiburg, Freiburg, Germany
4. St George’s Hospital NHS Trust, London, UK
Disclosure: Heinz Drexel has received fees from Amgen Inc., Boehringer Ingelheim (BI), Bayer Austria GmbH, Merck Sharp & Dohme (MSD), Eli-Lilly, Takeda, Novartis Austria GmbH, Novo Nordisk, Abbott, Bristol-Myers Squibb (BMS), Sanofi-Aventis, Pfizer Corporation Austria, and AstraZeneca Österreich for speaker honoraria and/or consulting. Jørgen Rungby has received research support from Eli-Lilly and Novo Nordisk, and consultancy fees from Eli-Lilly, Sanofi Aventis, Novo Nordisk, Takeda, and Astra Zeneca. Jochen Seufert has received fees from Takeda, Bayer, Novartis, MSD, Astra Zeneca, BMS, Novo Nordisk, Sanofi Aventis, Berlin Chemie, Lilly, BI, Merck, Roche, Ipsen, Pfizer, Janssen, and Lifescan for speaker honoraria. He has received fees for advisory boards from Takeda, Bayer, Novartis, MSD, Astra Zeneca, BMS, NovoNordisk, Sanofi Aventis, Berlin Chemie, Lilly, BI, Roche, Ipsen, Pfizer, Janssen, Lifescan, and research support from Novartis, MSD, Novo Nordisk, Sanofi Aventis, Ipsen, and Pfizer. Kausik Ray has received honoraria for advisory boards or lectures from Takeda, AstraZeneca, BI, and Novo Nordisk.
Acknowledgements: Writing assistance was provided by Dr Tabasum Mughal of apothecom scopemedical Ltd.
Support: Medical writing assistance was funded by Takeda. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Takeda.
Citation: EMJ Diabet. 2014;2:35-41.
This Takeda-sponsored European Association for the Study of Diabetes (EASD) symposium addressed the pharmacology, clinical use, and future therapeutic application of dipeptidyl-peptidase-4 (DPP-4) inhibitors. The scientific programme covered the clinical efficacy of DPP-4 inhibitors, their durability in clinical practice, and their use in combination therapy with other antidiabetic drugs. The important issue of the effect of this class of drugs on cardiovascular (CV) outcomes was also explored. The symposium was chaired by Prof Heinz Drexel and included insightful talks from an expert faculty comprising of Profs Jørgen Rungby, Jochen Seufert, and Kausik Ray.